Home
Kyverna Therapeutics

Kyverna Therapeutics Market Share Analysis for August 2026

Professor Georg Schett’s interests include basic, translational and clinical research on molecular and cellular pathogenesis of rheumatic and autoimmune diseases. In 2008, he initiated in collaboration with colleagues the priority program IMMUNOBONE, funded by the German Research Foundation (DFG), which aims to elucidate the interactions between the skeletal and the immune systems. Since 2015, Professor […]

Health > Biotechnology and Pharmaceuticals

Domainkyvernatx.com

Year Founded2018

Employees51 - 200

Annual Revenue--

Kyverna Therapeutics

Kyverna Therapeutics (including company regionals)

kyvernatx.com

See more website traffic and engagement information

Total visits to Kyverna Therapeutics's top domains

Understand Kyverna Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

kyvernatx.com14.1K

See more with Sales Intelligence

Avg. visit duration in Kyverna Therapeutics's top domains

Analyze Kyverna Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

kyvernatx.com00:00:56

See more with Sales Intelligence

Avg. pageviews on Kyverna Therapeutics's top domains

See how Kyverna Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

kyvernatx.com2.61

See more with Sales Intelligence

Kyverna Therapeutics top competitors by domain

Top similar sites in August 2026, ranked by their affinity

cartesiantherapeutics.comCompany NameCartesian TherapeuticsEmployees51 - 200HQUnited States, Maryland, GaithersburgAnnual revenue$2M - $5MTotal visits8.2KN/A

Top technologies used by Kyverna Therapeutics

These are the website technologies, by industry, used by Kyverna Therapeutics top domains

Widget (3)

Twemoji

Advertising (2)

DoubleClick

Audio Video Media (2)

YouTube

Conversion & Analytics (2)

Google Analytics

More Technologies

10

See all

News & Signals from Kyverna Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsKyverna Therapeutics, Inc. partnered with ElevateBio on Jul 27th '26.EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 - Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna's autologous CD19-directed CAR T-cell therapy.

NewsKyverna Therapeutics, Inc. identified as competitor of Vertex Pharmaceuticals on Jan 1st '26.Kyverna Therapeutics vs. Vertex Pharmaceuticals: which drug developer stock is a better buy in 2026?

NewsKyverna Therapeutics, Inc. attends event EULAR 2026.Kyverna Therapeutics' CD19-directed CAR T therapy, mivocabtagene autoleucel (miv-cel; KYV-101), delivered deep B-cell depletion, sustained autoantibody suppression, and durable clinical benefit in refractory rheumatoid arthritis, with updated Phase 1 COMPARE trial results presented at EULAR 2026.